[Expression pattern of invasion-related molecules in brain tumors of different origin]

Miklós Petrás1, Gábor Hutóczki, Imre Varga

  • 1Debreceni Egyetem Orvos- és Egészségtudományi Centrum Idegsebészeti Klinika, Debrecen.

Magyar Onkologia
|October 2, 2009
PubMed

Insights

Malignant gliomas invade brain tissue more than metastases. Researchers found significant differences in invasion-related molecules like epidermal growth factor receptors (EGFRs) and integrins between glioblastoma and metastatic tumors.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Tumor cell invasion into brain tissue hinders surgical resection and leads to recurrence.
  • Epidermal growth factor receptors (EGFRs), integrins, and extracellular matrix (ECM) molecules drive tumor cell adhesion and migration.
  • Malignant gliomas exhibit more extensive peritumoral invasion compared to metastatic tumors.

Purpose of the Study:

  • To investigate differences in mRNA and protein expression of invasion-related molecules between glioblastoma (GBM) and brain metastases.
  • To identify molecular mechanisms underlying glioblastoma's high invasiveness.

Main Methods:

  • Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to analyze mRNA expression of 29 invasion-related molecules.
  • Immunohistochemical analysis to confirm protein expression of nine key molecules.
  • Evaluation of fresh frozen human tissue samples from GBM and bronchial adenocarcinoma metastases.

Main Results:

  • Significant differences in mRNA expression were found for six molecules, including ErbB1, 2, 3, integrins alpha3, 7, and beta1.
  • Immunohistochemistry confirmed distinct protein staining differences for ErbB1, 2, integrins alpha3, and beta1.
  • These findings highlight molecular variations contributing to glioblastoma's invasive potential.

Conclusions:

  • Differences in invasion-related molecules between tumor types can elucidate GBM's peritumoral infiltration mechanisms.
  • Identifying these molecular targets may aid in developing targeted therapies for highly invasive malignant gliomas.